EUVIMEDEUVIMED entdecken
Open Access

Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis

Maxime Beydon, David Hajage, Alexis F Guédon, Fabrice Carrat, Raphaèle Seror, Florence Tubach

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.6579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Maxime Beydon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Institut pour la Santé et la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, Ass…. Hauptthemen laut MEDLINE: Aspirin, Giant Cell Arteritis, Primary Prevention, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with giant cell arteritis (GCA) face an increased risk of major adverse cardiovascular events (MACE). The benefit of low-dose aspirin in these patients is unknown.

Objective

To evaluate the 1-year association of low-dose aspirin with risk of MACE in primary prevention in patients with incident GCA and to evaluate the risk of major hemorrhage and net clinical benefit at predefined time points. Design, Setting, and Participants This population-based cohort study used a target trial emulation framework with a cloning, censoring, and weighting approach within the French National Health Data System. Participants were individuals aged at least 50 years with incident GCA between 2010 and 2022, without previous cardiovascular events or antiplatelet or anticoagulant use at GCA diagnosis. Analysis was conducted from November 2024 to June 2025. Exposure Initiation of low-dose aspirin vs not (control group) within 14 days of GCA diagnosis. Main Outcomes and Measures The main outcome was MACE, a composite end point of ischemic stroke, myocardial infarction, and all-cause mortality. Major hemorrhages were evaluated as secondary outcomes.

Results

A total of 14 528 individuals (median [IQR] age, 74 [67 to 80] years; 10 396 [72%] female), were included. Low-dose aspirin was initiated in 5220 individuals (36%). At 1 year, MACE risk was lower in the low-dose aspirin group (relative risk [RR], 0.86 [95% CI, 0.75 to 0.96]; risk difference [RD], −0.54% [95% CI, −0.99% to −0.12%]), while major hemorrhage risk was higher (RR, 1.29 [95% CI, 1.05 to 1.53]; RD, 0.51% [95% CI, 0.13% to 0.91%]). All-cause mortality was lower in the low-dose aspirin group at 1 year (RD, −0.43% [95% CI, −0.77% to −0.10%]). At 3 years, MACE events were less frequent in the low-dose aspirin group (RD, −1.08% [95% CI, −1.77% to −0.41%]), with no difference in major hemorrhages. A more pronounced association between low-dose aspirin and lower 1-year MACE was observed in women (RD, −0.78% [95% CI, −1.29% to −0.25%]) and patients with diabetes at GCA diagnosis (RD, −2.23% [95% CI, −3.48% to −1.02%]). Conclusions and Relevance In this retrospective cohort study, low-dose aspirin at GCA diagnosis was associated with lower MACE at 1 and 3 years but higher hemorrhage risk at 1 year. Subgroup analyses suggested heterogeneity according to sex and diabetic status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinGiant Cell ArteritisPrimary PreventionCardiovascular DiseasesPlatelet Aggregation InhibitorsHumansFemaleAgedMaleAged, 80 and overHemorrhageCohort StudiesFranceMiddle Aged

Substanzen

AspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Sorbonne Université, Institut pour la Santé et la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, Assistance Publique - Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Dépar…
  • Department of Internal Medicine, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Paris, France.
  • Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de santé publique, Hôpital Saint-Antoine, Assistance Publique - Hôp…
  • Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Center for Immunology of Viral Infections and Auto-immune Diseases, Institut pour la Santé et la Recherche Médicale UMR 1184, Université Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.

Zitieren

APA

Beydon, M., Hajage, D., Guédon, A. F., Carrat, F., Seror, R., & Tubach, F. (2026). Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.6579

Vancouver

Beydon M, Hajage D, Guédon AF, Carrat F, Seror R, Tubach F. Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.6579

BibTeX
@article{Beydon2026,
  author = {Beydon, Maxime and Hajage, David and Guédon, Alexis F and Carrat, Fabrice and Seror, Raphaèle and Tubach, Florence},
  title = {Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.6579}
}
Kostenlos starten →